Definium Therapeutics (DFTX) Total Non-Current Liabilities (2020 - 2026)

Definium Therapeutics (DFTX) has 7 years of Total Non-Current Liabilities data on file, last reported at $121.9 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $121.9 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $121.9 million (changed N/A YoY), and the FY2025 annual result was $107.3 million, changed N/A from the prior year.
• Total Non-Current Liabilities grew to $121.9 million in Q1 2026 per DFTX's latest filing, from $107.3 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $121.9 million in Q1 2026 and troughed at $7.9 million in Q2 2022.
• A 5-year average of $58.0 million and a median of $45.8 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities soared 71.91% in 2022, then surged 346.21% in 2023.
• A 5-year view of Total Non-Current Liabilities shows it stood at $17.9 million in 2022, then soared by 159.19% to $46.4 million in 2023, then surged by 71.34% to $79.5 million in 2024, then jumped by 35.01% to $107.3 million in 2025, then rose by 13.62% to $121.9 million in 2026.
• Business Quant data shows DFTX's Total Non-Current Liabilities at $121.9 million in Q1 2026, $107.3 million in Q4 2025, and $105.8 million in Q3 2025.